Inhibition of stat-1
CA 2461064 A1 · Owner: Avontec Gmbh · Inventors: Wagner, Andreas H.; Hecker, Markus
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to inhibitors of the transcription factor STAT-1 to , their use as therapeutic agents and to their use for the prevention or therapy of: cardiovascular complications such as restenosis after percutaneous angioplasty or the stenosis of vein bypasses; the graft-versus-host-reaction; ischaemia/reperfusion damage during surgery or organ transplant operations; immunological hypersensitivity reactions in particular allergic rhinitis or , allergies to medicaments and foodstuffs in particular urticaria and coeliac , disease (sprue); contact eczema and immunocomplex diseases in particular , alveolitis, arthritis, glomerulonephritis and vasculitis allergica; inflammatory …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 2, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 2, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 2, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.